ARIZ Precision Medicine (pronounced “Arise”) is developing first in class cancer therapeutics based on targeting PRDM oncogenes, a histone methyltransferase family that is disrupted in about 50% of cancers. ARIZ-047, a novel siRNA formulated in a calcium-phosphate drug delivery system with a tumor targeting ligand, is currently in advanced preclinical development for treating lung and other solid tumors. ARIZ-047 is the first compound demonstrating the ability of this powerful platform to rapidly identify first in class and best-in-class PRDM drug candidates, that are more effective than current therapeutic options. ARIZ currently has a robust portfolio of 7 drug candidates targeting the most common forms of cancer. ARIZ has won multiple awards for it's technology development, including being named Buzz of BIO in 2020, and winning 2nd prize (and $5000) at the Boston Chinese Investment Club's 2022 BioMedical pitch competition.